- Home
- ADCT vs GHI Comparison
ADCT vs GHI Comparison
Compare ADCT & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- GHI
- Stock Information
- Founded
- ADCT 2011
- GHI 1998
- Country
- ADCT Switzerland
- GHI United States
- Employees
- ADCT N/A
- GHI N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- GHI Finance: Consumer Services
- Sector
- ADCT Health Care
- GHI Finance
- Exchange
- ADCT Nasdaq
- GHI Nasdaq
- Market Cap
- ADCT 241.0M
- GHI 269.5M
- IPO Year
- ADCT 2020
- GHI N/A
- Fundamental
- Price
- ADCT $2.78
- GHI $12.11
- Analyst Decision
- ADCT Strong Buy
- GHI Strong Buy
- Analyst Count
- ADCT 6
- GHI 4
- Target Price
- ADCT $7.80
- GHI $16.00
- AVG Volume (30 Days)
- ADCT 937.9K
- GHI 40.8K
- Earning Date
- ADCT 08-05-2025
- GHI 08-06-2025
- Dividend Yield
- ADCT N/A
- GHI 12.22%
- EPS Growth
- ADCT N/A
- GHI N/A
- EPS
- ADCT N/A
- GHI 0.45
- Revenue
- ADCT $75,817,000.00
- GHI $34,065,322.00
- Revenue This Year
- ADCT $10.65
- GHI $228.92
- Revenue Next Year
- ADCT $15.05
- GHI $4.27
- P/E Ratio
- ADCT N/A
- GHI $27.06
- Revenue Growth
- ADCT 10.49
- GHI N/A
- 52 Week Low
- ADCT $1.05
- GHI $10.12
- 52 Week High
- ADCT $4.13
- GHI $15.31
- Technical
- Relative Strength Index (RSI)
- ADCT 47.62
- GHI 57.27
- Support Level
- ADCT $3.21
- GHI $11.70
- Resistance Level
- ADCT $3.97
- GHI $11.99
- Average True Range (ATR)
- ADCT 0.38
- GHI 0.31
- MACD
- ADCT -0.12
- GHI 0.03
- Stochastic Oscillator
- ADCT 3.43
- GHI 83.67
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.